You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Medtronic
Baxter
Moodys
Harvard Business School
McKinsey

Last Updated: November 24, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR IXAZOMIB CITRATE

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Ixazomib Citrate

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00963820 Study Evaluating the Safety and Tolerability of Weekly Dosing of Oral IXAZOMIB in Adult Patients With Relapsed and Refractory Multiple Myeloma Completed Millennium Pharmaceuticals, Inc. Phase 1 2009-10-01 The primary objective of this study is to determine the safety profile, tolerability, and maximum tolerated dose of ixazomib citrate (MLN9708) when taken orally on a weekly dosing schedule by patients with relapsed and refractory multiple myeloma (RRMM). Secondary objectives include pharmacokinetics and response rates.
NCT01415882 Ixazomib in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib Recruiting National Cancer Institute (NCI) Phase 2 2012-01-01 This randomized phase II trial studies how well ixazomib (ixazomib citrate) works in treating patients with multiple myeloma that has returned after a period of improvement but is not resistant to bortezomib. Ixazomib citrate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
NCT01415882 Ixazomib in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib Recruiting Mayo Clinic Phase 2 2012-01-01 This randomized phase II trial studies how well ixazomib (ixazomib citrate) works in treating patients with multiple myeloma that has returned after a period of improvement but is not resistant to bortezomib. Ixazomib citrate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
NCT01864018 Ixazomib Citrate, Cyclophosphamide, and Dexamethasone in Treating Patients With Previously Untreated Symptomatic Multiple Myeloma Suspended National Cancer Institute (NCI) Phase 1/Phase 2 2013-08-01 This phase I/II trial studies the side effects and the best dose of cyclophosphamide when given together with ixazomib and dexamethasone in treating patients with previously untreated symptomatic multiple myeloma. Drugs used in chemotherapy, such as cyclophosphamide and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Ixazomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving cyclophosphamide together with ixazomib and dexamethasone may be a better treatment for multiple myeloma.
NCT01864018 Ixazomib Citrate, Cyclophosphamide, and Dexamethasone in Treating Patients With Previously Untreated Symptomatic Multiple Myeloma Suspended Mayo Clinic Phase 1/Phase 2 2013-08-01 This phase I/II trial studies the side effects and the best dose of cyclophosphamide when given together with ixazomib and dexamethasone in treating patients with previously untreated symptomatic multiple myeloma. Drugs used in chemotherapy, such as cyclophosphamide and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Ixazomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving cyclophosphamide together with ixazomib and dexamethasone may be a better treatment for multiple myeloma.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Ixazomib Citrate

Condition Name

Condition Name for Ixazomib Citrate
Intervention Trials
Recurrent Plasma Cell Myeloma 11
Refractory Plasma Cell Myeloma 7
Plasma Cell Myeloma 6
Multiple Myeloma 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Ixazomib Citrate
Intervention Trials
Neoplasms, Plasma Cell 23
Multiple Myeloma 23
Lymphoma 4
Plasmacytoma 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Ixazomib Citrate

Trials by Country

Trials by Country for Ixazomib Citrate
Location Trials
United States 91
Brazil 15
Italy 12
United Kingdom 12
Japan 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Ixazomib Citrate
Location Trials
Minnesota 13
California 7
Georgia 5
Washington 5
New York 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Ixazomib Citrate

Clinical Trial Phase

Clinical Trial Phase for Ixazomib Citrate
Clinical Trial Phase Trials
Phase 3 4
Phase 2 16
Phase 1/Phase 2 8
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Ixazomib Citrate
Clinical Trial Phase Trials
Recruiting 19
Not yet recruiting 10
Active, not recruiting 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Ixazomib Citrate

Sponsor Name

Sponsor Name for Ixazomib Citrate
Sponsor Trials
National Cancer Institute (NCI) 24
Mayo Clinic 10
Millennium Pharmaceuticals, Inc. 7
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Ixazomib Citrate
Sponsor Trials
Other 29
NIH 24
Industry 12
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
McKesson
Medtronic
AstraZeneca
Dow
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.